Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test from a US Societal Perspective
Vladislav Berdunov,1 Gebra Cuyun Carter,2 Ewan Laws,1 Roger Luo,2 Christy A Russell,2 Sara Campbell,2 Yara Abdou,3 Jeremy Force4 1Putnam, London, UK; 2Exact Sciences, Madison, WI, USA; 3School of Medicine, UNC, Chapel Hill, NC, USA; 4School of Medicine, Duke University, Durham, NC, USACorrespondence...
Saved in:
Main Authors: | Berdunov V (Author), Cuyun Carter G (Author), Laws E (Author), Luo R (Author), Russell CA (Author), Campbell S (Author), Abdou Y (Author), Force J (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
by: Berdunov V, et al.
Published: (2022) -
Spotlight on the utility of the Oncotype DX® breast cancer assay
by: Siow ZR, et al.
Published: (2018) -
The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers
by: Pascale A. Cohen, et al.
Published: (2019) -
Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer
by: Mislick K, et al.
Published: (2014) -
Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center
by: Dániel Deme, et al.
Published: (2024)